NICE favors drugs from Celgene, GSK-Valeant

We're looking at two thumbs up and one thumb down from the U.K.'s cost-effectiveness watchdog. The National Institute for Health and Clinical Excellence recommended Celgene's thalidomide as a first-line mutiple myeloma treatment. NICE also gave an initial nod to Trobalt, the new epilepsy treatment from GlaxoSmithKline and Valeant Pharmaceuticals.

But NICE once again nixed Johnson & Johnson's Velcade as an initial multiple myeloma treatment. In final draft guidance, the agency said thalidomide--given in combination with two other drugs--should come first. Any patients who can't tolerate the Celgene treatment could then substitute Velcade in the three-drug cocktail.

Why not Velcade in the beginning? NICE said that both drug regimens seemed to be clinically effective. But oral therapy with thalidomide costs an average of £2,100 pounds ($3,400) per treatment cycle, compared with £3,000 for Velcade, which is given intravenously. Apparently the combination of price and ease of therapy put thalidomide in front.

"Although the choice of treatment would differ for each individual, a thalidomide regimen would be considered more suitable for most patients," NICE's Carole Longson said in a statement, adding that thalidomide treatment was also more cost-effective.

- see NICE's press release
- read the Bloomberg story
- get more from Reuters

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.